

DAFTAR PUSTAKA

- Allredge, B. K. et al., 2013. *Koda-Kimble & Young's Applied Therapeutics The Clinical Use of Drugs*. 10th ed. Philadelphia: Lippincott Williams & Wilkins. pp. 932-940.
- Aquaretta, I., Aldaz, A., Giraldez, J. & Sierrasesumaga, L., 2002. Pharmacodynamics of High Dose Methotrexate in Pediatric Patients. *Annals Pharmacotherapy*, Volume 36, pp. 1344-50.
- Arceci, R., Hann, I. & Smith, O., 2006. Pediatric hematology. In: 3rd ed. United Kingdom: Blackwell Publishing, p. 455
- Armstrong, S. & Look, A., 2005. Molecular Genetics of Acute Lymphoblastic Leukemia. *Journal of Clinical Oncology*, Volume 23, pp. 6306-6315.
- Bleyer, W. & Dedrick, R., 1978. Clinical pharmacology of intrathecal methotrexate pharmacokinetics in nontoxic patients after lumbar injection. *Cancer Treatment Reports*, Volume 61, pp. 703-8.
- Borsi, J. D. & Moe, P. J., 1987. Systemic Clearance of Methotrexate in the Prognosis of Acute Lymphoblastic Leukemia in Children. *Cancer*, pp. 3020-3024.
- Bostrom, B., Erdmann, G. & Kamen, B., 2003. Systemic Methotrexate Exposure Is Greater After Intrathecal Than After Oral Administration. *Journal of Pediatric Hematology/Oncology*, pp. 114-117.
- Cheng, D. H. et al., 2018. Identification of Risk Factors in High-Dose Methotrexate-Induced Acute Kidney Injury in Childhood Acute Lymphoblastic Leukemia. *Karger Chemotherapy*, Volume 63, pp. 100-106.
- Choi, G., Kim, T. H., Oh, J. M. & Choy, J. H., 2018. Emerging nanomaterials with advanced drug delivery functions; focused on methotrexate delivery. *Elsevier*, pp. 32-51.
- Cooper, S. L. & Brown, P. A., 2015. Treatment of Pediatric Acute Lymphoblastic Leukemia. *Pediatric Acute Lymphoblastic Leukemia*, Volume 62, pp. 61-73.
- Csordas, K. et al., 2014. Associations of novel genetic variations in the folate-related and ARID5B genes with the pharmacokinetics and toxicity of high-

- dose methotrexate in paediatric acute lymphoblastic leukemia. *British Journal of Haematology*, pp. 1-11.
- Csordas, K. et al., 2013. Comparison of pharmacokinetics and toxicity after high-dose methotrexate treatments in children with acute lymphoblastic leukemia. *Wolters Kluwer Health*, pp. 189-197.
- Estey, E., Faderl, S. & Kantarjian, H., 2008. Hematologic Malignancies: Acute Leukemias. In: New York: Springer Berlin Heidelberg, p. 77.
- Evans, W. et al., 1986. Clinical Pharmacodynamics of High Dose Methotrexate in Acute Lymphoblastic Leukemia. *The New England Journal of Medicine*, 8(314), pp. 471-476.
- Evans, W. et al., 1979. Pharmacokinetic Monitoring of High Dose Methotrexate. *Cancer Chemotherapy and Pharmacology*, Volume 3, pp. 161-166.
- Evans, W. et al., 1998. Conventional Compared with Individualized Chemotherapy for Childhood Acute Lymphoblastic Leukemia. *The New England Journal of Medicine*, 338(8), pp. 499-505.
- Figg, W. & McLeod, H., 2004. In: *Handbook of Anticancer Pharmacokinetics and Pharmacodynamics*. New Jersey: Humana Press, p. 405.
- Gronroos, M. et al., 2008. Long Term Follow Up of Renal Function After High Dose Methotrexate Treatment in Children. *Pediatric Blood Cancer*, Volume 51, pp. 535-539.
- Hallworth, M. & Capps, N., 1993. Therapeutic Drug Monitoring and Clinical Biochemistry. In: London: ACB Venture Publications, pp. 70-73.
- Hempel, L. et al., 2003. Influence of High Dose Methotrexate Therapy (HD-MTX) on Glomerular and Tubular Kidney Function. *Medical Pediatric Oncology*, Volume 40, pp. 348-354.
- Hempel, L. et al., 2003. Influence of High-Dose Methotrexate Therapy (HD-MTX) on Glomerular and Tubular Kidney Function. *Med Pediatr Oncol*, Volume 40, pp. 348-354.
- Howard, S. C. et al., 2016. Preventing and Managing Toxicities of High-Dose Methotrexate. *The Onkologist*, Issue 21, pp. 1-12.
- Hunger, S. & Mullighan, C., 2015. Acute Lymphoblastic Leukemia in Children. *The New England Journal of Medicine*, pp. 1541-1552.

- IDAI, 2013. Indonesian Protocol Acute Lymphoblastic Leukemia (ALL). In: Jakarta: s.n.
- IDAI, 2018. Indonesian Protocol Acute Lymphoblastic Leukemia (ALL). In: Jakarta: s.n.
- Inaba, H., Greaves, M. & Mullighan, C., 2014. Acute lymphoblastic leukaemia. *Lancet*, pp. 1-27.
- Jacobs, S., Stoller, R., Chabner, B. & Johns, D., 1976. 7-Hydroxymethotrexate as a Urinary Metabolite in Human Subjects and Rhesus Monkeys Receiving High Dose Methotrexate. *The Journal of Investigation*, Volume 57, pp. 534-538.
- Jin, m., XU, S., An, q. & Wang, p., 2016. A review of risk factors for childhood leukemia. *European Review for Medical and Pharmacological Sciences*, pp. 3760-3764.
- Joannon, P., Oviedo, I., Campbell, M. & Tordecilla, J., 2004. High Dose Methotrexate Therapy of Childhood Lymphoblastic Leukemia: Lack of Relation Between Serum Methotrexate Concentration and Creatinine Clearance. *Pediatric Blood Cancer*, Volume 43, pp. 17-22.
- Jolivet, J. et al., 1983. The Pharmacology and Clinical Use of Methotrexate. *The New England Journal of Medicine*, 309(18), pp. 1094-1101.
- Kalthi, V. et al., 2018. Improving the safety of high-dose methotrexate for children with hematologic cancers in settings without access to MTX levels using extended hydration and additional leucovorin. *Pediatr Blood Cancer*, pp. 1-6.
- Kapoor, G., Sinha, R. & Abedin, S., 2012. Experience With High Dose Methotrexate Therapy in Childhood Acute Lymphoblastic Leukemia in a Tertiary Care Cancer Centre of a Developing Country. *Pediatric Blood Cancer*, pp. 1-6.
- Katz, A., Chia, V., Schoonen, W. & Kelsh, M., 2015. Acute lymphoblastic leukemia: an assessment of international incidence, survival, and disease burden. *Cancer Causes Control*, pp. 1627-1642.
- Kliegman, R., Stanton, B. & Geme, J., 2016. Nelson Textbook of Pediatrics, 20th Ed. In: Philadelphia: Elsevier, pp. 2437-2444.

- Korell, J. et al., 2013. Comparison of intracellular methotrexate kinetics in red blood cells with the kinetics in other cell types. *British Journal of Clinical Pharmacology*, pp. 493-497.
- Lankelma, J. et al., 1980. Change in Transfer Rate of Methotrexate from Spinal Fluid to Plasma during Intrathecal Therapy in Children and Adults. *Clinical Pharmacokinetics*, pp. 465-475.
- Lanzkowsky, P., Lipton, J. & Fish, J., 2016. Lanzkowsky's Manual of Pediatric Hematology and Oncology Sixth Edition.
- Leather, H. & Poon, B., 2008. Pharmacotherapy: A Pathophysiologic Approach. In: *Pharmacotherapy: A Pathophysiologic Approach*. 7th ed. New York: McGrawHill Co, pp. 2259-2266.
- Lennard, L., 1999. Therapeutic drug monitoring of antimetabolic cytotoxic drugs. *British Journal of Clinical Pharmacology*, Volume 47, pp. 131-143.
- Maxwell, R. R. & Cole, P. D., 2017. Pharmacogenetic Predictors of Treatment-Related Toxicity Among Children With Acute Lymphoblastic Leukemia. *Curr Hematol Malig Rep*, Issue 12, pp. 176-186.
- McPhee, S. & Hammer, G., 2014. Pathophysiology of Disease: An Introduction to Clinical Medicine. In: 7th ed. USA: McGrawHill, p. 105.
- Mei, L. et al., 2015. Pharmacogenetics predictive of response and toxicity in acute lymphoblastic leukemia therapy. *Elsevier*, Issue 29, pp. 243-249.
- Murakami, T. & Mori, N., 2012. Involvement of Multiple Transporters-mediated Transport in Mizoribine and Methotrexate Pharmacokinetics. *Pharmaceuticals*, Volume 5, pp. 802-836.
- NCCN, 2017. Guideline for Acute Lymphoblastic Leukemia. pp. 1-91.
- Niemann, A. et al., 2010. Therapeutic Drug Monitoring of Methotrexate in Cerebrospinal Fluid After Systemic High-Dose Infusion in Children: Can the Burden of Intrathecal Methotrexate be Reduced?. *Therapeutic Drug Monitoring*, pp. 467-475.
- Nizzamani, G., Nizamani, Z., Fahim, A. & Ujjan, I., 2016. Acute lymphoblastic leukemia; chromosomal abnormalities in childhood reporting at a tertiary care hospital of Sindh. *Professional Med Journal*, 23(3), pp. 312-316.

- Pan, S., Li, Z., He, Z. & Qiu, J., 2016. Molecular mechanisms for tumour resistance to chemotherapy. *Clinical and Experimental Pharmacology and Physiology*, pp. 723-737.
- Paolini, S. et al., 2011. Pathobiology of Acute Lymphoblastic Leukemia. *Seminars in Diagnostic Phatology*, Volume 28, pp. 124-134.
- Perazella, M., 1999. Crystal-induced Acute Renal Failure. *The American Journal of Medicine*, Volume 106, pp. 459-465.
- Permono, B. et al., 2012. *Buku Ajar Hematologi-Onkologi Anak*. 4th ed. Jakarta: Ikatan Dokter Anak Indonesia.
- Permono, B. et al., 2012. Leukemia Akut. In: I. D. A. Indonesia, ed. *Buku Ajar Hematologi-Onkologi Anak*. Jakarta: s.n., pp. 236-247.
- Peter H, W., Janice P, D. & Morie A, G., 2018. *Neoplastic Diseases of the Blood*. switzerland: Springer.
- Pizzo, P. & Poplack, D., 2006. *Principles & Practice of Pediatric Oncology*. 5th ed. USA: Lippincott Williams & Wilkins.
- Popovic, J. K. et al., 2015. Fractional model for pharmacokinetics of high dose methotrexate in children with acute lymphoblastic leukaemia. *Elsevier*, pp. 451-471.
- Pui, C., Robison, L. & Look, A., 2008. Acute Lymphoblastic Leukemia. *The Lancet*, Volume 371, pp. 1030-43.
- Ramsey, L. B. et al., 2018. Consensus Guideline for Use of Glucarpidase in Patients with High-DoseMethotrexate Induced Acute Kidney Injury and DelayedMethotrexate Clearance. *The Onkologist*, Issue 23, pp. 52-61.
- Rau, T., Erney, B., Eschenhagen, T. & Beck, J., 2006. High-dose methotrexate in pediatric acute lymphoblastic leukemia: Impact of ABCC2 polymorphisms on plasma concentrations. *Clinical Pharmacology & therapeutics*, Volume 80, pp. 468-476.
- Ronco, C., Bellomo, R. & Kellum, J., 2009. *Critical Care Nephrology*. 2nd ed. Philadelphia: Saunders Elsevier.
- Rudin, S., Marable, M. & Huang, S., 2016. The Promise of Pharmacogenomics in Reducing Toxicity During Acute Lymphoblastic Leukemia Maintenance Treatment. *Elsevier*, Issue 15, pp. 82-93.

- Sahni, V., Choudhury, D. & Ahmed, Z., 2009. Chemotherapy-associated renal dysfunction. *Nature*, Volume 5, pp. 450-462.
- Schmiegelow, K. et al., 2016. Maintenance therapy of childhood acute lymphoblastic leukemia revisited—Should drug doses be adjusted by white blood cell, neutrophil, or lymphocyte counts?. *Wiley Pediatric Blood Cancer*, Issue 00, pp. 1-8.
- Schwartz, G., Haycock, G., Edelmann, C. & Spitzer, A., 1976. A Simple Estimate of Glomerular Filtration Rate in Children Derived from Body Length and Plasma Creatinine. *Pediatrics*, Volume 58, pp. 259-263.
- Singh, A. et al., 2017. PLGA-soya lecithin based micelles for enhanced delivery of methotrexate: Cellular uptake, cytotoxic and pharmacokinetic evidences. *Elsevier*, pp. 750-756.
- Skarby, T. et al., 2003. High-dose methotrexate: on the relationship of methotrexate elimination time vs renal function and serum methotrexate levels in 1164 courses in 264 Swedish children with acute lymphoblastic leukaemia (ALL). *Cancer Chemotherapy Pharmacology*, Volume 51, pp. 311-320.
- Stephen P, H. & Charles G, M., 2015. Acute Lymphoblastic Leukemia in Children. *N Engl J Med*, pp. 1541-1552.
- Umerez, M. et al., 2017. MTHFR polymorphisms in childhood acute lymphoblastic leukemia: influence on methotrexate therapy. *Pharmacogenomics and Personalized Medicine*, Issue 10, pp. 69-78.
- Utomo, F. N., Yulistiani, Zairina, N. & Permono, B., 2017. Methotrexate Use is Safe in Children with Acute Lymphoblastic Leukemia. *Folia Medica Indonesiana*, 53(2), pp. 144-151.
- WHO, 2008. Acute Lymphoblastic Leukemia in Children: A Brief Review of The Internationally Available Protocols.
- Widemann, B. & Adamson, P., 2006. Understanding and Managing Methotrexate Nephrotoxicity. *The Oncologist*, Volume 11, pp. 694-703.
- Xu, W.-q., Zhang, L.-y. & Chen, X.-y., 2014. Serum creatinine and creatinine clearance for predicting plasma methotrexate concentrations after high-dose methotrexate chemotherapy for the treatment for childhood lymphoblastic malignancies. *Cancer Chemother Pharmacol*, Volume 73, pp. 79-86.

- Yang, S. L. et al., 2015. Methotrexate Associated Renal Impairment Is Related to Delayed Elimination of High-Dose Methotrexate. *The ScientificWorld Journal*, pp. 1-8.
- Yeoh, A. et al., 2017. Treatment delay and the risk of relapse in pediatric acute lymphoblastic leukemia. *Pediatric Hematology and Oncology*, pp. 1-5.
- Zgheib, N. K. et al., 2014. Genetic polymorphisms in candidate genes predict increased toxicity with methotrexate therapy in Lebanese children with acute lymphoblastic leukemia. *Pharmacogenetics and Genomics*, Volume 24, pp. 387-396.
- Zuckerman, T. & Rowe, J., 2014. Pathogenesis and Prognostication in Acute Lymphoblastic Leukemia. Volume 6, pp. 1-5.